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Background: The control of vector-borne diseases is important to improve human and animal health worldwide.
Malaria is one of the world’s deadliest diseases and is caused by protozoan parasites of the genus Plasmodium,
which are transmitted by Anopheles spp. mosquitoes. Recent evidences using Subolesin (SUB) and Akirin (AKR)
vaccines showed a reduction in the survival and/or fertility of blood-sucking ectoparasite vectors and the infection
with vector-borne pathogens. These experiments suggested the possibility of using AKR for malaria control.
Methods: The role of AKR on Plasmodium berghei infection and on the fitness and reproduction of the main
malaria vector, Anopheles gambiae was characterized by evaluating the effect of akr gene knockdown or vaccination
with recombinant mosquito AKR on parasite infection levels, fertility and mortality of female mosquitoes.
Results: Gene knockdown by RNA interference in mosquitoes suggested a role for akr in mosquito survival and fertility.
Vaccination with recombinant Aedes albopictus AKR reduced parasite infection in mosquitoes fed on immunized mice
when compared to controls.
Conclusions: These results showed that recombinant AKR could be used to develop vaccines for malaria control. If
effective, AKR-based vaccines could be used to immunize wildlife reservoir hosts and/or humans to reduce the risk of
pathogen transmission. However, these vaccines need to be evaluated under field conditions to characterize their effect
on vector populations and pathogen infection and transmission.
Keywords: Akirin, Arthropod, Mosquito, Subolesin, Vaccine, MalariaBackground
Malaria, one of the world’s deadliest diseases, is caused
by protozoan parasites of the genus Plasmodium which
are transmitted by Anopheles spp. mosquitoes [1]. Last
malaria report from WHO, estimates that 3.4 billion
people were at disease risk in 2013 [2]. Plasmodium spp.
have a complex multi-stage life cycle involving two hosts,
primary host (mosquito) and secondary host (human)
occurring in different cellular environments [3].
Recently, methodologies for diagnosis and integrated
vector control by various physical and chemicals methods
have been improved or implemented and research to
develop vaccines against malaria is being carried on by* Correspondence: adomingos@ihmt.unl.pt
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unless otherwise stated.several groups around the world [3]. The development
of a vaccine against malaria has been a difficult task,
mainly due to the complexity of the parasite life cycle
and the equally complex and multifaceted host immune
responses [4]. Malaria vaccines targeting the blood stage
are considered as anti-disease vaccines as they prevent
or reduce clinical disease but do not prevent infection
[4]. An efficacious pre-erythrocytic vaccine would block
disease by inhibiting parasites to reach the blood stream
and preventing transmission. The RTS,S/AS is an example
of a candidate pre-erythrocytic vaccine at phase III field
trials performed in eleven African research centres [5,6].
However, the first results from these trials were not as
good as expected [7]. Recently, another pre-erythrocytic
candidate vaccine based on whole attenuated sporozoites
has been developed; phase I trials were concluded showing
several weaknesses such as the need for intravenous
administration of very high number of sporozoites toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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individuals [8]. This could be overcome by transmission-
blocking vaccines that specifically intend to target
molecules that are exclusive to gametocytes or to other
mosquito stages. Antibodies against these targets are
capable of blocking the development of parasite sexual
stages and, therefore, interrupt transmission. A vaccine
based on mosquito-stage proteins of both Plasmodium
falciparum and Plasmodium vivax was shown to produce
dose-dependent antibody-mediated transmission-blocking
activity but showed to be unacceptably reactogenic [9].
Preliminary results obtained in arthropod vectors with
impact on human and animal health have shown that
protective antigens may be used for the development of
vaccines against both vectors and pathogens they transmit
[10-18]. Among these antigen candidates, tick Subolesin
(SUB) and the ortholog in insects, Akirin (AKR), have
been used to induce a protective response in vaccinated
hosts for the control of hard (Ixodes spp., Rhipicephalus
spp., Amblyomma americanum, Dermacentor variabilis)
and soft (Ornithodoros spp.) ticks, mosquitoes (Aedes
albopictus), sand flies (Phlebotomus perniciosus), poultry
red mites (Dermanyssus gallinae) and sea lice (Caligus
rogercresseyi) infestations and tick infection with Ana-
plasma phagocytophilum, A. marginale, Babesia bigemina
and Borrelia burgdorferi [15,19-21]. These results suggest
that vaccines based on AKR/SUB antigens could control
vector-borne diseases by a dual effect on vector popula-
tions and vector capacity [15,16].
SUB/AKR intermediate proteins interactions with
NF-kB and other regulatory proteins bind DNA and
remodel chromatin to regulate gene expression of signal
transduction and innate immune response genes and tran-
scriptional regulators [16,22-24]. This broad function of
SUB/AKR as transcription factors explains the profound
effect of gene knockdown by RNAi on tick and insect
physiology, as well as on development and gene expres-
sion in ticks [15,16]. SUB and AKR are functionally
important for arthropod innate immunity and, at least
in ticks, for tissue development and function and for
pathogen infection and multiplication [16,25].
A connection between the expression of mosquito
AKR and Plasmodium spp. infection has not yet been
established. However, several studies linked Anopheles
gambiae NF-kB–like transcription factor REL2 to anti-
parasitic defenses [26,27]. These results together with
the need to develop effective vaccines for malaria control
have encouraged research on the possibility of using
AKR for the control of An. gambiae populations and the
infection with Plasmodium parasites.
The role of AKR on Plasmodium berghei infection and
on the fitness and reproduction of the main malaria
vector, An. gambiae was characterized by evaluating
the effect of akr gene knockdown or vaccination withrecombinant mosquito AKR on infection rate, parasite
burdens, fertility and mortality of female mosquitoes.
Methods
Ethical statement
Animals were housed at the Instituto de Higiene e
Medicina Tropical, in strict accordance with the rec-
ommendations of the Europe Directive 86/609/ EEC
and Portuguese law (Decreto-Lei No. 129/92). Animal
experiments were conducted with the approval of the
Divisão Geral de Alimentação e Veterinária (DGAV),
Portugal, under Art° 8, Portaria n°1005/92 from 23rd
October (permit number n° 023357). At the end of the
experiment, mice were anesthetized before being eu-
thanized by cervical disruption.
Mosquitoes
The An. gambiae s.s. (molecular M form) of the Yaoundé
strain mosquitoes were obtained from the Instituto de
Higiene e Medicina Tropical (IHMT) insectary and
reared at 26°C and 75% humidity on a 12/12 hour light/
dark cycle. Adult mosquitoes were maintained on a 10%
glucose solution.
Anopheles gambiae infection with Plasmodium berghei
To obtain An. gambiae mosquitoes infected with P. berghei
for gene expression and gene knockdown analyses, four
weeks old female CD1 mice obtained from the IHMT
animal house were intraperitoneally inoculated with 107
P. berghei parasitized red blood cells. GFP (PbGFPCON),
a recombinant P. berghei strain that constitutively ex-
presses GFP in the cytoplasm from a transgene con-
trolled by the elongation factor-1-alpha gene promoter
was used [28]. Parasitaemia were determined from
blood samples collected from mouse tail, using light
microscopy after methanol fixation of air-dried blood
smears and staining with 10% (w/v) Giemsa. When the
parasitaemia reached 10–20% and exflagellation was
observed (4–6 exflagellations/field), mice were used to
infect mosquitoes. Female mosquitoes (N = 200/mice)
were allowed to feed directly on P. berghei infected mice
(N = 3) for 30–45 minutes. Unfed female mosquitoes
were removed from the cage. Fully engorged mosquitoes
were kept at 19-21°C and 80% humidity for P. berghei
development.
Characterization of mosquito akr gene expression after
parasite infection
The P. berghei infected and uninfected female mosquitoes
were dissected. Midguts and the abdomen carcass (herein
after denominated fat body) were stored in ice-cold RNA
later (Ambion, Austin, TX, USA). Tissues were used
immediately or stored at −20°C until RNA extraction.
Pools of 30 infected/uninfected midguts and fat body
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Nucleospin RNAII kit (Macherey-Nagel, Bethlehem,
USA) following the manufacturer’s instructions. First
strand cDNA was synthesized using oligo dT and MMLV
Reverse Transcriptase (Promega, Madison, USA). The
akirin (Vectorbase: AGAP006809) expression levels were
determined by qPCR using gene-specific oligonucleotide
primers (5’- CCCTGTTCACCTTCAAGCAG-3’ and
5’- GGTCAGCACGGCATCATACT-3’) and iQ™ SYBR
Green supermix in the iCycler iQ™ (Bio-Rad, Hercules,
CA, USA) following the manufacturer’s recommenda-
tions. Fluorescence readings were taken at 62°C after
each cycle and a melting curve was obtained to confirm
the identity of the PCR product. Experiments were
made in triplicate. The mRNA levels were normalized
against ribosomal protein S7 gene (RPS7; Vectorbase:
AGAP010592) using oligonucleotide primers (5’-GCC
ATCCTGGAGGATCTGGTA-3’ and 5’-CGATGGTGG
TCTGCTGTTCTTATCC-3’) and the comparative ΔΔCt
method [29]. Normalized mRNA levels were compared
between infected and control mosquitoes by Student’s
t-test with unequal variance (P = 0.05).
Mosquito akr gene knockdown
RNAi was used to characterize the effect of akr gene
knockdown in mosquitoes [30,31]. The akr specific primers
containing T7 promoter sequences at the 5’-end were
synthesized (Table 1) and using the MEGAscript T7 kit
(Ambion, Austin, TX, USA) dsRNA was produced
according to manufacturer’s instructions. An exogenous
gene, mouse beta-2 microglobulin (B2m) (GenBank:
NM_009735) was used as control and the dsRNA was
synthesized in a similar way (Table 1). The dsRNA was
diluted in sterile water to a concentration of 3 mg/ml and
concentration and quality were assessed by spectrometry
and agarose gel. For gene knockdown, 600 female mos-
quitoes were used (200 mosquitoes/mouse). Cold anes-
thetized three day old-female mosquitoes were injected
intrathoraxically with 69 nl of dsRNA using a nano-
injector (Nanoject; Drummond Scientific, Broomall, PA,
USA). The control group was injected with B2m dsRNA.
Four days after dsRNA injection gene knockdown was
analyzed by RT qPCR and the remaining mosquitoes wereTable 1 Gene-specific primers and conditions used for dsRNA
Gene (accession number) Upstream/downstream primer seq
TAATACGACTCACTATAGGGTACTTTGGCAG
Mosquito akirin (AGAP006809)
TAATACGACTCACTATAGGGTACTCACCTGC
TAATACGACTCACTATAGGGAGACACCCCCA
Mouse B2m (NM_009735)
TAATACGACTCACTATAGGGAGACACCCCCA
T7 promoter sequences (5’-TAATACGACTCACTATAGGGTACT-3’) were included at thfed on a mouse infected with P. berghei and kept as above
for parasite development. Surviving mosquitoes were
counted and dissected 8 days after feeding. Midguts were
mounted on coverslips and oocysts visualized under a
fluorescent microscope to determine infection intensity
(median number of parasite oocyst per infected mosquito)
and the number of eggs in the ovaries. Infection rate
(100 × [number of infected mosquitoes/total number of
mosquitoes analysed]) was evaluated. Pools of approxi-
mately 30 infected/uninfected midguts and fat body were
used to determine akr mRNA levels by RT-qPCR as de-
scribed before. Normalized mRNA levels and the number
of mosquitoes that survived dsRNA injection were com-
pared between akirin dsRNA-injected and control mos-
quitoes injected with unrelated B2m dsRNA by Student’s
t-test with unequal variance (P = 0.05). The number of
parasite oocysts and eggs in mosquito midguts and the
number of surviving mosquitoes were compared between
akr dsRNA-injected and control mosquitoes injected with
unrelated B2m dsRNA by a two-sample comparison using
the non-parametric Mann–Whitney test (P = 0.0001).
Mouse immunization and infection challenge
Recombinant AKR from Ae. albopictus was produced as
previously reported using an extractive bioconversion
process in an aqueous two-phase system supporting
Pichia pastoris growth and protein secretion and used
on immunization trials adjuvated in Montanide ISA
50 V2 (Seppic, Paris, France) [13,17,18]. Five weeks old
female Balb/c mice (N = 5 per group) were obtained from
the IHMT animal facility and used for the immunization
trial. Mice were immunized intraperitoneally with 4 doses
of 0.1 ml each containing 20 μg of recombinant AKR
emulsified (1:1) with the adjuvant Montanide ISA 50 V2
(Seppic, Paris, France) [22] two weeks apart. Mice were
immunized with AKR or adjuvant/saline and then infected
with P. berghei or left uninfected as control. Two weeks
after the last immunization, mice were infected with
P. berghei by direct bite of infected mosquitoes. Thirty
female mosquitoes, 3–5 days old, fed on each mouse
for 30–45 minutes. After infective blood meal, only
fully engorged females were transferred to individual
vials for oviposition. Egg cups were removed sevensynthesis
uence (5’-3’) Fragment size (bp) PCR annealing conditions
TCGTTGTAGTTGC
509 52°C/1 min
TTGAAGGTGAACA
CTGAGACTGATACA
447 62°C/45 sec
CTGAGACTGATACA
e 5’-end for dsRNA synthesis.
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survival at 8 days post-infestation was also evaluated.
Infection rate and infection intensity were determined
as described before. Mosquito infection challenge was
performed in three independent experiments. Results
from mosquitoes fed on AKR-immunized and control
mice were compared by Student’s t-test with unequal
variance (P = 0.05).
Determination of serum antibody levels by ELISA
Before each immunization and two weeks after the last
immunization mouse tail blood was collected to prepare
sera for analysis of antibodies titers against AKR by an
indirect enzyme-linked immunosorbent assay (ELISA).
A high binding 96 well-ELISA plate (Costar®, MA, USA)
was incubated overnight at 4°C with 0.1 μg of recombin-
ant protein per well diluted in 100 μl PBS. After antigen
incubation, the plate was washed twice with tris buffered
saline (25 mM Tris HCl, 150 mM NaCl, 2 mM KCl)
containing 0.05% (v/v) Tween 20 (TBST), blocked with
200 μl of 5% (w/v) milk (BioRad, Hercules, CA, USA) at
room temperature for one hour and washed three times
with TBST. Serum samples were incubated for one hour
at 37°C. The secondary anti-mouse AP-conjugated immu-
noglobulins (Sigma-Aldrich, St. Louis, Missouri, USA)
were diluted 1:10,000 in TBST supplemented with 0.1%
(w/v) BSA (Sigma-Aldrich, St. Louis, Missouri, USA),
added to wells and incubated for one hour at 37°C. After
washing 5 times with TBST, plates were incubated with
1 mg/ml of p-nitrophenil phosphate in substrate buffer
(100 mM glycine, 1 mM MgCl2, 1 mM ZnCl2, pH 10.4) at
room temperature in the dark. To stop the reaction,
100 μL of 3 M NaOH was added to each well. Plates were
then red in a microplate reader (BioRad model 550) at a
wavelength of 405 nm and analyzed with the Microplate
manager 4.0 software (BioRad). Antibody titers were de-
termined at a 1:6,400 serum dilution and were compared
between AKR-immunized and control mice by Student’s
t-test with unequal variance (P = 0.0001).
Results
The akr gene knockdown resulted in reduced mosquito
survival and egg production and increased parasite
infection
For the characterization of akr gene expression in response
to parasite infection, adult female mosquitoes were
infected with P. berghei. Mice were infected with P. berghei
or left uninfected as control. Twenty-four hours post-
infection, adult female mosquitoes were fed on mice to
characterize akr expression in midguts and fat body
tissues. To characterize the in vivo effect of akr knockdown
by RNAi on mosquito biology and parasite infection, in-
jection of akr and unrelated B2m control dsRNAs was
performed in 600 female mosquitoes fed on 3 differentinfected mice (200 mosquitoes/mouse). The akr gene
mRNA levels were significantly lower in akr dsRNA-
injected mosquitoes when compared to dsRNA controls
(P < 0.05) with gene silencing ranging from 16-40% in
the midgut and 25-65% in the remaining tissues.
The effect of akr gene knockdown on mosquito mortality,
egg production and P. berghei infection were characterized.
Mosquito survival, evaluated six days after infectious blood
meal, was higher in akr dsRNA-injected mosquitoes when
compared to controls (Figure 1A). However, at day-8 post-
infectious blood feeding (day 12 post-injection), survival
was 14% lower in mosquitoes with akr gene knockdown
(Figure 1A). The akr gene knockdown also reduced egg
production by 52% when compared to control mosquitoes
injected with B2m dsRNA (Figure 1B). However, parasite
infection, determined by different parameters was higher
in mosquitoes with akr knockdown when compared to
controls (Figures 1C-F).
Anti-AKR antibodies reduced P. berghei infection in
An. gambiae fed on immunized mice
To evaluate the effect of antibodies against AKR on the
malaria vector An. gambiae and the infection with P. ber-
ghei, mice were immunized with recombinant mosquito
AKR or placebo and infected with P. berghei parasites or
left uninfected as controls. Mouse antibody titers increased
after the first immunization with recombinant AKR and
remained significantly higher until the end of the experi-
ment in both AKR-immunized infected and uninfected
mice when compared to controls (Figure 2). Different to
akr knockdown, survival was not affected in mosquitoes
fed on immunized mice when compared to mosquitoes fed
on control mice (Figure 3A). Also in contrast to RNAi
results, parasite infection was lower (Figures 3B-D) and egg
production was higher (Figures 2E and F) in mosquitoes
fed on immunized infected mice when compared to mos-
quitoes fed on control infected mice. Particularly relevant
was the effect on infection intensity, which was reduced in
more than 60-fold in mosquitoes fed on immunized mice
when compared to controls (Figure 2C). Egg production
was significantly lower in mosquitoes fed on immunized
uninfected mice when compared to mosquitoes fed on
control infected mice (Figure 2E).
Discussion
The WHO estimates that 207 million cases of malaria and
627,000 deaths occurred globally in 2012. The mosquito
An. gambiae is the major vector of parasites causing
malaria in sub-Saharan Africa [2]. The increasing preva-
lence of malaria is attributed to the rapid spread of drug-
resistant parasites, insecticide-resistant mosquitoes and
the absence of a protective vaccine. Our studies were
focused on understanding the role of mosquito AKR, a
conserved nuclear factor required for innate immune
Figure 1 Effect of mosquito akr gene knockdown. Mosquitoes (N = 3 experiments of 200 mosquitoes each) were injected with dsRNA and
fed 4 days later on P. berghei–infected mice. Surviving mosquitoes were counted and dissected to collect midguts 8 days after feeding (day 12
post-injection) to determine infection intensity (median number of parasite oocyst per infected mosquito), infection rate (100 × [number of
infected mosquitoes/total number of mosquitoes analyzed]), number of parasite oocyst in mosquito midguts, number of eggs in the ovaries and
the number of surviving mosquitoes. (A) Surviving mosquitoes. (B) Number of eggs per ovary. (C) Number of oocyst per midgut. (D) Representative
fluorescence images of parasite oocyst in mosquito midguts. (E) Representative results for infection intensity. (F) Representative results for infection
rate. Similar results were obtained in all replicates (N = 3). The number of parasite oocyst/midgut and eggs/ovary and the number of surviving
mosquitoes (Ave ± SD) were compared between akr dsRNA-injected and control mosquitoes injected with unrelated B2m dsRNA by a two-sample
comparison using the non-parametric Mann–Whitney test (*P < 0.0001).
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vector and Plasmodium parasite and the potential of this
protein as a protective vaccine antigen. As previously
shown, tick SUB and mosquito AKR are good protective
antigen candidates for the control of both vector infesta-
tions and pathogen infection [15,16,25].
RNA interference-based akr knockdown in mosquitoes
was performed as previously reported for other target genes
[32]. Obtained data suggests that, as in prior experiments
concerning to akr/sub RNAi assays in flies [22] and ticks
[33-36], mosquito survival and egg production were re-
duced after gene knockdown, supporting the role of AKR
in immune response. RNAi mediated knockdown led to anincrease of parasite infection in An. gambiae mosquitos
after feeding on infected mice as reported for akr knock-
down in flies infected with Agrobacterium tumefasciens
[22]. Also in white shrimps (Litopenaeus vannamei) akr
mRNA levels are strongly induced in response to Vibrio
parahaemolyticus infection and akr silencing lead to high
mortality after infection challenge [37]. The effect of Akr
silencing on infection level is probably due to the impair of
Imd pathway signaling enhancing the sensitivity to bacterial
and parasite infection [15,16,22,25]. The increase of Plas-
modium parasites levels after gene silencing shows that
AKR/SUB is required for defense against pathogens and for
the regulation of genes that are important for infection.
Figure 2 Mice immunization with AKR. Antibody titers were
determined by ELISA and compared between AKR-immunized and
control mice by Student’s t-test with unequal variance (*P < 0.0001).
Immunization shots are represented with arrows.
Figure 3 Effect of immunization with AKR on mosquito biology and inf
or adjuvant/saline and then infected with P. berghei or left uninfected as cont
representative fluorescence images of parasite oocyst in mosquito midguts. (C
obtained in all replicates (N = 5). (D) Representative results for infection rate. S
eggs per ovary. (F) Oviposition (representative results for the number of laid e
The number of parasite oocyst/midgut, eggs/ovary and the number of surviv
on immunized and control infected mice by a two-sample comparison using
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antigen for vaccine development against vector infesta-
tions. Thus, to determine whether AKR could represent a
novel target for an An. gambiae infestations control and
also to determine its influence on Plasmodium infection
process, we vaccinated mice with recombinant AKR from
Ae. albopictus.
Following silencing data, AKR vaccination was expected
to primarily reduce An. gambiae reproductive and survival
parameters since it has been reported that this protein is
related not only to the embryonic development of insects
[38] or involved in muscle development [39] but also
influences infection levels due to its immunity related
functions. Previous immunization experiments using
this antigen showed a reduction in the oviposition and
fertility of Ae. albopictus mosquitoes fed on immunized
uninfected mice when compared to controls [17,18].ection with P. berghei. Mice were immunized with recombinant AKR
rols. (A) Surviving mosquitoes. (B) Number of oocyst per midgut with
) Representative results for infection intensity. Similar results were
imilar results were obtained in all replicates (N = 5). (E) Number of
ggs/mosquito; similar results were obtained in all replicates; N = 5).
ing mosquitoes (Ave ± SD) were compared between mosquitoes fed
the non-parametric Mann–Whitney test (*P < 0.0001).
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AKR immunized uninfected mice but AKR did not
affect An. gambiae survival after feeding on immunized
mice in accordance to other reports [17,18].
Antibodies against recombinant AKR significantly
reduced the infection on An. gambiae by P. berghei sug-
gesting that AKR might contribute to the development
of vaccines against malaria by reducing parasite infec-
tion levels in vector mosquito species. In opposition of
what was expected, results suggest that blocking the
AKR protein in the cells did not distress Imd pathway
but rather we may be targeting protein translocation
disturbing, thus, the cell response to infection [25].
The protection elicited by the anti-mosquito vaccine is
based on the production antibodies in the vaccinated mice
that may interact and affect the function of the target
antigen (AKR) leading to a response against Plasmodium
proteins. The development of vaccines against blood-
sucking arthropod ectoparasites such as mosquitoes is
based on the concept that ectoparasites ingest antigen-
specific antibodies when feeding on immunized hosts.
These antibodies interact with the protective antigen in
the arthropod to affect the function and/or quantity of the
protein, resulting in reduced survival, reproduction and/or
infection with vector-borne pathogens. For SUB/AKR,
the mode of action of the antibodies is not completely
understood but may be the result of antibodies crossing
the cell membrane and interacting with the protein in
the cytoplasm to prevent protein translocation to the
nucleus [15,16,25,35,40]. The issue of vaccine safety with
antigens such as AKR that are conserved between inverte-
brate and vertebrate hosts has been addressed before,
suggesting in a low risk to induce autoimmune responses
in vertebrate hosts [17,18,33].Conclusions
In summary, the results reported here showed that re-
combinant AKR could be used to develop vaccines for
malaria control. If effective, AKR-based vaccines could
be used to immunize wildlife reservoir hosts and/or
humans to reduce the risk of pathogen transmission.
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